MeSH

A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.

Year introduced: 1987

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS.

Year introduced: 1978(1964)

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

Year introduced: 1988

Multiple ring heterocyclic compounds containing two or more rings that share two atoms and one bond in common.

Year introduced: 2017

Chemicals with two conjoined aromatic rings incorporating two nitrogen atoms and one of the carbons oxidized with a keto oxygen.

Year introduced: 2007

Cyclic compounds that include atoms other than carbon in their ring structure.

Organic compounds that contain a ring structure made up of carbon and one or more additional elements such as nitrogen and oxygen.

Year introduced: 1998

A class of heterocyclic compounds that include a two-ring fused structure. Both aromatic and non-aromatic ring structures are included in this category.

Year introduced: 1998

A family of hexahydropyridines.

Year introduced: AZACYCLONOL was heading 1963-1984

A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.

Year introduced: 1966(1965)

Substances used for their pharmacological actions on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function.

Year introduced: 1998

Drugs used for their effects on serotonergic systems. Among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons.

Year introduced: 1995

A group of pharmacologic activities, effects on living systems and the environment, and modes of employment of drugs and chemicals. They are broken into actions, which describe their effects, and uses, which describe how they are employed.

Year introduced: 1999

A broad category of chemical actions and uses that result in the prevention, treatment, cure or diagnosis of disease. Included here are drugs and chemicals that act by altering normal body functions, such as the REPRODUCTIVE CONTROL AGENTS and ANESTHETICS. Effects of chemicals on the environment are also included.

Year introduced: 2004(1999)

Pharmacological activities at the molecular level of DRUGS and other exogenous compounds that are used to treat DISEASES and affect normal BIOCHEMISTRY.

Year introduced: 2008(2004)

Drugs that act on blood and blood-forming organs and those that affect the hemostatic system.

Year introduced: 1998

Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.

Year introduced: 1979

Activities which affect organs and systemic functions without regard to a particular disease.

Year introduced: 2004

Uses of chemicals which affect the course of conditions, diseases, syndromes or pathology to benefit the health of an individual.

Year introduced: 2004